COV up +3.13% percent Today $COV High is at 98.32 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
COV up +3.13% percent Today $COV High is at 98.32 and the Low 94.66 with current volume of 1,549,868.

Recent News posted below.

Covidien Plc. COV other info.
http://investorshangout.com/Covidien-Plc-COV-50596/

COV Covidien Plc. Recent Headline News

InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST

HCOM: 26.98 (-0.03), IPHI: 14.20 (+0.58), JBHT: 80.00 (+0.24), COV: 97.76 (+3.15), OPHT: 40.19 (+0.04), COP: 71.23 (-0.19), SFM: 31.22 (+0.31), GOOG: 539.30 (+2.79), GSAT: 2.60 (-0.20), STAY: 18.54 (-0.02), ZOES: 32.98 (-0.20), INTX: 3.81 (+0.07), GNRC: 43.27 (+1.39), HZNP: 12.75 (+0.25), TRUE: 17.80 (+0.20)

Covidien's Test Data Positive for VenaSeal Closure System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:10PM CST
Covidien plc (COV) recently announced six-month results from the VeClose pivotal study, which was carried out to evaluate the safety and efficiency of the VenaSeal closure system, a treatment option for chronic venous disorders.
JNJ: 109.03 (+0.73), BDX: 130.31 (+0.77), BCR: 166.90 (+2.09), COV: 97.76 (+3.15)

Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015
Thomson Reuters ONE - Mon Nov 17, 11:30AM CST

MDT: 71.83 (+2.64), COV: 97.76 (+3.15)

Six Month Results of VeClose Study Demonstrate Safety, Effectiveness of the VenaSeal(TM) Closure System
Business Wire - Thu Nov 13, 5:00PM CST
Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system* in patients with chronic venous insufficiency (CVI) having symptomatic reflux in the great saphenous vein. The results were presented at American College of Phlebology Annual Congress (ACP 2014) in Phoenix, Ariz.
COV: 97.76 (+3.15)

Form 8.1 - Covidien
Business Wire - Thu Nov 13, 10:17AM CST
Covidien plc:
COV: 97.76 (+3.15)

Insider Trading Alert - CTSH, PSEC And COV Traded By Insiders
at The Street - Thu Nov 13, 9:15AM CST
Stocks with insider trader activity include CTSH, PSEC and COV
COV: 97.76 (+3.15), CTSH: 52.83 (-0.23), PSEC: 9.64 (-0.02)

Covidien Shares Up 28.9% Since SmarTrend's Buy Recommendation (COV)
Comtex SmarTrend(R) - Wed Nov 12, 9:16AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 6 months, Covidien has returned 28.91% as of today's recent price of $93.02.
COV: 97.76 (+3.15)

Wall Street Breakfast: Global Banks Fined $3.4B In Forex Probe
Wall Street Breakfast - Seeking Alpha - Wed Nov 12, 5:30AM CST
Economy Japanese stocks scaled seven-year highs this morning on further speculation that Prime Minister Shinzo Abe will postpone a planned sales tax hike and call a general election for December. The Sankei newspaper reported that Abe would...
VRX: 141.28 (+4.55), MDT: 71.82 (+2.63), C: 54.06 (+0.49), WMT: 83.91 (+0.34), RBS: 11.99 (+0.07), UBS: 17.50 (+0.05), NOK: 7.98 (+0.31), YHOO: 51.58 (-0.79), PBR: 8.90 (-0.43), SPY: 205.23 (+0.86), SAP: 68.48 (+0.96), EBAY: 55.01 (+0.18), JPM: 60.72 (+0.34), BHP: 57.35 (-0.84), AAPL: 114.43 (+0.44), BCS: 14.89 (+0.19), FRM: 6.33 (+0.21), COV: 97.76 (+3.15), HSBC: 50.00 (-0.05), FRGI: 56.56 (+0.90), ZTS: 43.85 (-0.38), DLA: 10.62 (+0.10), QQQ: 103.49 (+0.58), AOL: 46.19 (-0.52), BABA: 111.19 (-3.06)

Medtronic submits concessions for $43B Covidien takeover
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:53AM CST

MDT: 71.82 (+2.63), COV: 97.76 (+3.15)

Insider Trading Alert - TSLA, COV And AKS Traded By Insiders
at The Street - Tue Nov 11, 9:08AM CST
Stocks with insider trader activity include TSLA, COV and AKS
TSLA: 258.13 (+4.15), COV: 97.76 (+3.15), AKS: 6.41 (-0.03)

Covidien Set to Possibly Pullback After Yesterday's Rally of 1.69%
Comtex SmarTrend(R) - Mon Nov 10, 3:57PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $92.19 to a high of $93.74. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $93.68 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.76 (+3.15)

Watch for Covidien to Potentially Pullback After Gaining 1.69% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 3:57PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $92.19 to a high of $93.74. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $93.68 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.76 (+3.15)

Quarterly Financial Results, Study Results, and Appointments - Research Reports on Covidien, Community Health, Express Scripts, Caterpillar and Boeing
PR Newswire - Fri Nov 07, 7:35AM CST
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Community Health Systems, Inc. (NYSE: CYH), Express Scripts Holding Company (NASDAQ: ESRX), Caterpillar Inc. (NYSE: CAT) and The Boeing Company (NYSE: BA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7772-100free.
ESRX: 79.46 (+0.40), CYH: 48.51 (+2.01), COV: 97.76 (+3.15), CAT: 101.51 (-0.19), BA: 129.87 (+1.45)

Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 8.51 (+0.11), MDT: 71.82 (+2.63), UNIS: 2.89 (+0.06), COV: 97.76 (+3.15), SHPG: 209.00 (+3.01), ABBV: 65.78 (+0.74), WAG: 67.40 (+0.85)

Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 260.34 (+12.40), COV: 97.77 (+3.16), CTSH: 52.83 (-0.23), TW: 113.87 (+0.85)

SmarTrend Watching for Potential Pullback in Shares of Covidien After 1.36% Gain
Comtex SmarTrend(R) - Wed Nov 05, 4:08PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $92.69 to a high of $93.68. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $92.89 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.77 (+3.16)

Covidien Announces Nine-Month Results of DURABILITY Iliac Study, Addition of Iliac Indication for EverFlex(TM) Stent System at VIVA 2014
Business Wire - Wed Nov 05, 3:06PM CST
Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex(TM) stent at the Vascular Interventional Advances (VIVA) 2014 conference. The nine-month results confirm the safety and effectiveness of the EverFlex(TM) and Protege(TM) GPS(TM) self-expanding stent systems* for the treatment of lesions of the common and external iliac arteries.
COV: 97.77 (+3.16)

Covidien (COV) Beats on Q4 Earnings, Sales; Both Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:50PM CST
Covidien plc (COV) reported fourth-quarter fiscal 2014 earnings of $1.15 per share, which beat the Zacks Consensus Estimate by 14 cents.
MDT: 71.82 (+2.63), GWPH: 79.17 (+2.61), ABAX: 54.99 (+0.33), COV: 97.77 (+3.16)

Covidien Plc. (COV) Stock Research Links

COV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Automotive Key Blank Market Insights for Smart Keys Growth

Updated Category News Views 97

The Expanding Landscape of the Automotive Key Blank Market The automotive key blank market is experiencing a transformative phase, poised to grow from USD 6.29 billion in 2025 to an impressive USD 9.67 billion by 2034. This remarkable growth reflects the industry’s ongoing adaptation to technological advancements, particularly the rising adoption of smart and automated...

Continue Reading
Innovations Drive Growth in the Meat Processing Equipment Sector

Updated Category News Views 231

Insights into the Expanding Meat Processing Equipment Market The global meat processing equipment market is anticipated to experience significant growth, projected to reach USD 16.36 billion by 2032. This remarkable increase from its value of USD 11.25 billion in 2024 represents a robust compounded annual growth rate (CAGR) of 4.86% from 2025 to 2032. The factors driving...

Continue Reading
Fed's Waller Advocates Rate Cuts in December Amid Labor Weakness

Updated Category News Views 173

Fed's Waller Emphasizes Importance of Rate Cuts Christopher Waller, a Governor at the Federal Reserve, has spoken out about the economic challenges facing the labor market. He is advocating for a reduction in the Fed’s policy rate during the next meeting, scheduled for December. His approach centers on the need to address the risks associated with a weakening labor...

Continue Reading
GIA-L Expands Innovation and Leadership with New Chapter Launch

Updated Category News Views 270

Global Initiative on Ageing and Longevity Launches U.S. Chapter The Global Initiative on Ageing and Longevity (GIA-L) has propelled its mission forward by launching a North American Chapter. This initiative is designed to accelerate innovation and foster significant business growth while addressing the changing demographics and needs of an aging population. The GIA-L...

Continue Reading
Deadline Alert: Faruqi & Faruqi's Investigation for Investors

Updated Category News Views 47

Investigating Extreme Networks: What You Need to Know Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into possible claims on behalf of investors in Extreme Networks, Inc. (NASDAQ: EXTR). The firm is reaching out to investors who have incurred losses exceeding $100,000 to discuss their options and legal rights. With the situation...

Continue Reading